If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 9 of 9
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Relapsing Forms of Multiple Sclerosis (RMS) or Pr
Objective
Dose Escalation Study of CC-97540 in RMS or PM
Protocol No
NEURO-BMS-CA061-1006
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multip
Objective
BIIB091 and BIIB091 Combined with Diroximel Fumarate in Relapsing MS
Protocol No
NEURO-BIOGEN-FUSION
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (Nmdar) Or Anti-Leuci
Objective
Satralizumab in NMDAR or LGI1 Enchephalitis
Protocol No
NEURO-GENENTECH-CIELO
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib 100mg B.I.D. Versus Teriflunomide 14mg Q.D. in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-
Objective
Remibrutinib vs Teriflunomide in Relapsing MS
Protocol No
NEURO-NOVARTIS-LOU064
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament
Objective
Current Therapy vs Transition to Ofatumumab After NfL Elevation (SOSTOS)
Protocol No
NEURO-NOVARTIS-SOSTOS
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or in Addition to Baseline Therapy in Patients with Myelin Oligodendr
Objective
Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
Protocol No
NEURO-ROCHE-METEOROID
A Randomized, Double-Blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants with Nonrelapsing Secondary Progressive Multiple Sclerosis
Objective
Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Nonrelapsing Secondary Progressive MS
Protocol No
NEURO-SANOFI-EFC17504
Master Protocol of Two Independent, Randomized, Double-Blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants with Relapsing Forms of Multiple Sclerosis
Objective
Master Protocol for SAR441344 to Teriflunomide in Relapsing MS
Protocol No
NEURO-SANOFI-EFC17919
REal World ExperieNce With BRIUMVI (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE)
Objective
Real World Experience with BRIUMVI for Relapsing MS
Protocol No
NEURO-TG-ENABLE